



Bayer AG
Communications
51368 Leverkusen
Germany
Tel. +49 214 30-1
media.bayer.com

News Release

Not intended for U.S. and UK Media

Bayer contributes an additional 50 million units of treatment to the World Federation of Hemophilia Humanitarian Aid Program

- 34 low-income countries are already benefiting from Bayer's recombinant Factor VIII (FVIII) treatments since the start of the partnership with the World Federation of Hemophilia (WFH) in May 2019
 - Bayer emphasizes that it will maintain its delivery of life-changing medicines to low-income countries
 - Bayer also renews its commitment to training and education as well as advocacy for patient access in low-income countries
-

Berlin, June 19, 2020 – During the Virtual Summit of the World Federation of Hemophilia (WFH), Bayer announced that it will continue to contribute 50 million units of hemophilia treatments to the WFH Humanitarian Aid Program, which aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in low-income countries. Bayer's vision of "Health for all, hunger for none" closely aligns with the aims of the WFH Humanitarian Aid Program's vision. Together, they can make progress towards achieving the Sustainable Development Goals and enabling better access to health for hemophilia patients. During the COVID-19 global health crisis and the current reduction of transport, Bayer and the WFH are working hard to maintain deliveries of life-changing medicines to people and minimize impact on patient care.

Since the start of the partnership in May 2019, the WFH Humanitarian Aid Program has delivered Bayer treatment products to 34 countries where access to treatment is limited. Bayer is one of the Program's main contributors and as part of the long-term partnership has committed 100 million units in total in 2019 and 2020, benefiting as many as 5,000 people living with hemophilia A per year.

“We are delighted to announce that we will contribute another 50 million units to the WFH Humanitarian Program for 2020, particularly as the current COVID-19 situation clearly shows that global challenges can be addressed if we act in solidarity” said Dr. Michael Devoy, Head of Medical Affairs & Pharmacovigilance of Bayer AG’s Pharmaceuticals Division and Bayer Chief Medical Officer. “Since the start of the partnership in 2019, we have already seen the tangible positive impact that the Bayer contributions have had, benefiting people across 34 countries. In recent weeks, we have seen how the importance of supplying health goods and services has come to the fore globally. Bayer is fully committed to supporting the hemophilia community, not only in the research and development of next-generation treatments, but also in ensuring those in need have access.”

“The lack of access to care and treatment in low-income countries is an urgent and important public health challenge and the WFH Humanitarian Aid Program aims to address this”, said Dr. Assad Haffar, Medical and Humanitarian Aid Director at WFH. “Now, more than ever, as the world faces a global health challenge like COVID-19, with low-income countries being hit hard, it is critical that we maintain humanitarian aid programs like this which provide people living with hemophilia with hope of better quality of life.”

Bayer’s contribution to the Program includes providing its full portfolio of recombinant FVIII treatments, which over the course of the partnership could benefit people in more than 60 countries where access to treatment is limited. To ensure that the Program has a sustainable impact on the communities, Bayer’s contribution also supports the training and education of healthcare professionals regarding the accurate and safe administration of treatments for acute bleeds, prophylaxis, surgeries and immune tolerance induction. With the support of Bayer the program is enabled to enroll children to prophylaxis therapy which prevents bleeds and disease complications.

About the WFH Humanitarian Aid Program

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, Founding

Visionary Contributors; Bayer, Visionary Contributor; Grifols and Roche, Leadership Contributors; and Contributor, CSL Behring. The WFH and WFH USA collaborate to manage and control the WFH Humanitarian Aid Program. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org

About Bayer in Hemophilia

Bayer is driven by helping people with hemophilia thrive. We have a deep understanding of the evolving needs and aspirations of people with hemophilia, established over 30 years of partnering with the hemophilia community. FVIII replacement therapy is the standard of care to stop or prevent bleeding. Bayer's portfolio of FVIII treatments offers people with hemophilia A across all stages of life a treatment to suit their individual needs and lifestyles. We work together with researchers, healthcare professionals and patient groups to build a strong community and help people with hemophilia to live fulfilling lives. Bayer is passionate about spearheading research and investing in developing the next generation of therapies, such as Gene Therapy and TFPI and solutions to help people with hemophilia thrive in the future.

About Hemophilia A

Hemophilia affects approximately 400,000 people around the world and is a largely inherited disorder in which one of the proteins needed to form blood clots is missing or reduced. Hemophilia A is the most common type of hemophilia, in which blood clotting is impaired because there is a lack or defect of coagulation FVIII. Patients repeatedly experience bleeds in muscles, joints or other tissues, which can result in chronic joint damage over time. Injuries can have severe consequences if not treated appropriately, as the blood clots more slowly in hemophilia patients than in healthy individuals. Hemophilia A has an estimated frequency of 1 in 5,000 male live births, affecting people worldwide. For example, there are approximately 6,000 people with the condition in France, 3,500 in Germany, and 13,000 in the U.S. today.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the

world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Contact:

Dr. Dieter Hilla, phone +49 214 30 58992

Email: dieter.hilla@bayer.com

Find more information at www.pharma.bayer.com

Our online press service is just a click away: media.bayer.com

Follow us on Facebook: <http://www.facebook.com/pharma.bayer>

Follow us on Twitter: [@BayerPharma](https://twitter.com/BayerPharma)

dhi (2020- 0152e)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.